Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 17/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275883 | 0.73 | CRHR1 (0.43) | CRHR1TP53HSD11B1KDM4E | |
| SCHEMBL28929204 | 0.72 | CYP1A2 (0.45) | TP53KDM4E | |
| SCHEMBL15466628 | 0.70 | CRHR1 (0.46) | CRHR1TP53 | |
| SCHEMBL10313479 | 0.69 | CRHR1 (0.52) | CRHR1 | |
| SCHEMBL13517062 | 0.68 | MAPT (0.65) | CRHR1TP53KDM4E | |
| SCHEMBL25117979 | 0.67 | MAPT (0.57) | TP53KDM4E | |
| SCHEMBL15466340 | 0.67 | KDM4E (0.50) | CRHR1TP53KDM4E | |
| SCHEMBL19668801 | 0.66 | MAPT (0.53) | TP53KDM4E | |
| SCHEMBL15020632 | 0.66 | TP53 (0.79) | CRHR1TP53KDM4E | |
| SCHEMBL2964886 | 0.66 | NPC1 (0.47) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045779-A1 | COMPOUNDS CONTAINING AN ALICYCLIE STRUCTURE AND ANTI-TUMOR APPLICATION | XU LIFENG (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045779-A1 | COMPOUNDS CONTAINING AN ALICYCLIE STRUCTURE AND ANTI-TUMOR APPLICATION | ALPI, SI, SLC5A11 | CRHR1 4305/4885TP53 11/4885HSD11B1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.